Kytopen Secures $3.6M Seed Funding to Advance Non-Viral Gene Editing Platform for Cell Therapies

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on May 28, U.S. local time, biotechnology company Kytopen completed a $3.6 million seed funding round. The proceeds from this round will be used to support the company’s development of gene-editing technologies for the treatment of cellular diseases.

It is reported that this round of financing was led by The Engine, with participation from Horizons Ventures.

Headquartered in Massachusetts, USA, Kytopen is a biotechnology company focused on gene modification technologies, dedicated to advancing cell therapy standards in the healthcare industry.

Flowfect™ is the company’s flagship technology platform, enabling scalable cell therapies without the use of viral vectors. Researchers can directly intervene in the gene delivery process on this platform and perform continuous gene editing operations using automation technologies. Furthermore, the platform is compatible with molecular complexes of various sizes, facilitating uninterrupted research.

Traditional viral vectors are limited to short-range transport and require sterile conditions for research, resulting in high costs and poor compatibility—a major challenge in the field of cell therapy. The Flowfect™ platform eliminates the need for viral vectors by directly intervening in the gene editing process, thereby enhancing the efficiency of cellular diagnostics and therapeutics, reducing the transportation costs of medical materials, and pioneering a new model for the healthcare industry.

Currently, Kytopen is working to integrate gene editing technology with automated liquid handling systems and expand the capacity of its Flowfect™ platform.

Paulo Garcia, CEO and Co-Founder of Kytopen, stated, “Gene-modified cell therapies hold the potential to treat incurable diseases, fundamentally transforming traditional medical practices. However, gene-modification approaches currently face significant challenges in efficiency, reproducibility, and manufacturing costs. We are grateful for the support from our new round of investors; we will leverage this funding to continue expanding our business operations and further optimize our cell therapy platforms.”

Kate Rae, CEO and Managing Partner of The Engine, added, “We are highly optimistic about Kytopen’s growth prospects. Since the inception of our partnership, Kytopen’s rapid development has drawn significant attention across the industry. We believe this disruptive gene therapy will gradually permeate the entire sector. We are delighted to invest in Kytopen once again and remain committed to helping the company expand its market presence and optimize its business operations.”

The Engine, founded by the Massachusetts Institute of Technology (MIT) in 2016 and headquartered in Massachusetts, USA, is a venture capital firm dedicated to investing in the early-stage development of startups in the field of innovative technologies. It has completed seven investments to date. In addition to providing financial support to companies, the firm also integrates their advanced technologies to foster mutual growth for both parties.

Horizons Ventures, also known as Li Ka-shing’s Horizons Ventures, is a venture capital firm founded by Li Ka-shing in 2006, primarily investing in startups focused on technology or disruptive innovations. Key executives at Horizons Ventures include Zhou Kaixuan (Solina Chau) and Zhang Peiwei. By 2016, Horizons Ventures had invested in 73 companies, with its portfolio spanning Europe, Asia, and the Americas.

(Compiled by Liu Yujing)